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Humans with dominant-negative (DN) mutations in PPAR-Y develop early onset hypertension. A recent
study by Pelham et al. (2012) shows that loss of PPAR-Y repression of the Rho kinase pathway leads
to altered vascular function via a smooth-muscle-dependent pathway that is independent of NO and
oxidant stress.PPAR-Y is a ligand-activated transcrip-
tion factor that is targeted by the thiazoli-
dinedione (TZD) class of antidiabetes
medications and is known to be important
in the regulation of adipogenesis and
type II diabetes (Beyer et al., 2008).
Activation of PPAR-Y by TZD drugs
improves insulin sensitivity and lowers
blood pressure in type II diabetics; how-
ever, individuals with dominant-negative
(DN) mutations of PPAR-Y not only
present with type II diabetes and severe
insulin resistance, but also exhibit early
onset hypertension via unknown mecha-
nisms (Barroso et al., 1999). This early
onset hypertension is mimicked in trans-
genic mice with a similar mutation. In
this issue, Pelham et al. (2012) utilize
one of these transgenic models to identify
mechanisms by which a DN mutant
form of PPAR-Y, expressed specifically
in the smooth muscle, causes enhanced
contraction and impaired vascular relaxa-
tion, leading to hypertension. The study
reveals a pathway in which smooth
muscle-specific PPAR-Y and Cullin-3, a
member of the E3-ubiquitin ligase com-
plex, participate in the regulation of vas-
cular smooth muscle tone and, possibly,
in the regulation of arterial blood pressure.
The authors find that mice with the DN
PPAR-Y mutation exhibit increased vas-cular contraction, impaired relaxation,
and elevated blood pressure similar to
the phenotypes found in various forms of
human hypertension; and that these alter-
ations are associated with increases in
RhoA and Rho-kinase activity. They
further show that this upregulation of the
Rho kinase pathway is related to reduced
expression and decreased neddylation
(conjugation of the ubiquitin-like protein
Nedd8) to Cullin-3, which normally
reduces the expression and activity of
RhoA by promoting its degradation in
the proteasome. Phenotypes similar to
those in mice expressing the DN PPAR-Y
mutation could be produced in wild-type
mice by treating them with a pharmaco-
logical agent (MLN4924) that inhibits the
neddylation of Cullin-3.
One gap in existing knowledge is the
mechanism by which Cullin-3 is regulated
by PPAR-Y. Cullin-3 is a cullin-RING E3
ubiquitin ligase complex scaffold protein
that regulates the turnover of RhoA
(Chen et al., 2009). The present study
provides evidence that Cullin-3 is down-
regulated in mice with the DN PPAR-Y
mutation, and that this occurs via sup-
pression of RhoBTB1, a novel PPAR-Y
target gene that may regulate the target-
ing of some Cullin-3 substrates, including
RhoA, for proteasomal degradation viathe Cullin-3 E3 RING ubiquitin ligase
complex.
A particularly attractive feature of the
study is the linking of this pathway to
vascular regulation in intact blood
vessels, in this case the aorta, rather
than exclusive use of cultured cell
models. The authors found that vascular
relaxation in response to acetylcholine
and the NO donor sodium nitroprusside
were impaired in mice harboring the DN
mutation of PPAR-Y. The investigators
provide convincing evidence that altered
vascular function in aortas of these mice
is mediated by a mechanism other than
changes in NO availability or elevated
vascular oxidant stress. This finding is
significant, given the multitude of studies
showing the importance of NO and reac-
tive oxygen species as major mediators
of pathophysiological changes in multiple
cardiovascular disorders. Other mecha-
nisms of potential importance have
seldom been sought.
The authors also show that systemic
administration of MLN4924 leads to an
elevated blood pressure in wild-type
mice. This is a potentially important
finding because it provides support for a
whole-body effect of the Cullin-3 mecha-
nism, a proof of concept that cannot be
obtained with in vitro studies of molecular
Cell Metabolism
Previewsmechanisms operating in cultured cells.
However, the potential existence of off-
target effects of the inhibitor must be
considered when interpreting these
findings.
The current study raises several impor-
tant questions regarding DN PPAR-Y
mutations. Do the alterations observed
by the authors also apply to the small
arteries that play the major role in regu-
lating vascular resistance in the peripheral
circulation (either uniformly, or in crucial
vascular beds such as the kidney and
brain) (see Beyer et al., 2008)? What is
the relative importance of smooth muscle
(Pelham et al., 2012) versus endothelial
(Beyer et al., 2008) expression of PPAR-Y
mutations in determining the ultimate
phenotype in intact blood vessels? How
does the mutation affect other crucial
end points in cardiovascular disease,
e.g., end organ damage, blood-flow
regulation, and responses to circulatory
stress? Finally, what are the exact mech-
anisms responsible for the chronically
elevated blood pressure in the mice
carrying the DN mutation of PPAR-Y?Nonetheless, this study provides
valuable insight into the possible mecha-
nisms by which dominant negative muta-
tions in PPAR-Y may lead to altered
vascular reactivity and elevated blood
pressure. From a vascular biology stand-
point, the finding of a substantial vascular
alteration that is independent of oxidant
stress and NO availability is especially
interesting and worthy of further investi-
gation. The results also have important
clinical implications, as some patients
presenting with early onset hyperten-
sion and insulin resistance carry muta-
tions in the PPAR-Y ligand-binding
domain, which leads to dominant nega-
tive activity (Barroso et al., 1999; Savage
et al., 2003). Furthermore, activation of
PPAR-Y by thiazolidinedione insulin-
sensitizing drugs such as rosiglitazone
attenuates the development of hyperten-
sion and inhibits atherosclerosis in
patients with type II diabetes, but the
mechanisms mediating the vascular
effects of PPAR-Y are poorly understood.
Because these commonly used drugs
have a number of serious side effectsCell Metabolism 1(Graham et al., 2010), it is evident that
a greater understanding of this pathway
will be required to provide appropriate
drug targets.REFERENCES
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Distinctive metabolism associated with particular cell states is increasingly being defined in normal and
malignant cells. Ito et al. (2012) now show that fatty acid oxidation is associated with hematopoietic stem
cells and determines whether they undergo symmetric or asymmetric cell division, driving a fundamental
property of the stem cell state.Increased attention to the metabolism of
malignant cells has raised the issue of
just how different they are from their
normal counterparts. This is particularly
of interest in the context of cell functions
such as self-renewal, shared by both
malignant cells and normal stem cells.
Whether the process of self-renewal has
distinct metabolic requirements in cancerand normal cells is unclear, but is of
potential consequence as therapies tar-
geting cancer cell metabolism move
toward the clinic. Work by the Pandolfi
laboratory now adds a new topic for
consideration in this rapidly evolving field.
Ito et al. show that fatty acid metabolism
is central to a signature feature of hemato-
poietic and other tissue stem cells, the‘‘decision’’ between self-renewal and
differentiation (Ito et al., 2012).
The metabolism of hematopoietic stem
and progenitor cells (HSPCs) has gener-
ally been studied with a focus on the
relative importance of glycolysis versus
oxidative phosphorylation. HSPCs are
known to depend upon HIF-1a, for
example, and while this gene has many6, October 3, 2012 ª2012 Elsevier Inc. 411
